Critical Survey: Future FinTech Group (NASDAQ:FTFT) and Phreesia (NYSE:PHR)

Future FinTech Group (NASDAQ:FTFT) and Phreesia (NYSE:PHR) are both small-cap retail/wholesale companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Future FinTech Group and Phreesia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Future FinTech Group	-202.56%	-97.68%	-66.99%
Phreesia	-20.43%	-32.78%	-22.37%

Risk and Volatility

Future FinTech Group has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Phreesia has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Institutional & Insider Ownership

0.2% of Future FinTech Group shares are owned by institutional investors. Comparatively, 92.1% of Phreesia shares are owned by institutional investors. 7.1% of Future FinTech Group shares are owned by insiders. Comparatively, 5.8% of Phreesia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Future FinTech Group and Phreesia”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Future FinTech Group	$34.87 million	0.16	-$33.65 million	N/A	N/A
Phreesia	$356.30 million	4.44	-$136.88 million	($1.47)	-18.52

Future FinTech Group has higher earnings, but lower revenue than Phreesia.

Analyst Recommendations

This is a summary of recent recommendations for Future FinTech Group and Phreesia, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Future FinTech Group	0	0	0	0	0.00
Phreesia	0	0	12	0	3.00

Phreesia has a consensus target price of $31.00, suggesting a potential upside of 13.85%. Given Phreesia’s stronger consensus rating and higher probable upside, analysts clearly believe Phreesia is more favorable than Future FinTech Group.

Summary

Phreesia beats Future FinTech Group on 9 of the 12 factors compared between the two stocks.

About Future FinTech Group

Future FinTech Group Inc., through its subsidiaries, operates online shopping platforms in People’s Republic of China. It operates in three segments: Supply Chain Financing Service and Trading Business, Asset Management Service, and Others. The company offers cross-border money transfer service, brokerage and investment banking, and cryptocurrency mining farm business. It also engages in the trading of coal, aluminum ingots, sand, and steel; and E-commerce, digital wallet safety management, blockchain code auditing and operations, cryptocurrency mining, metaverse and big data maintenance services. The company was formerly known as SkyPeople Fruit Juice, Inc. and changed its name to Future FinTech Group Inc. in June 2017. Future FinTech Group Inc. is headquartered in New York, New York.

About Phreesia

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.